Bellevue Asset Management

Bellevue Asset Management

Bellevue Asset Management

Overview
Date Founded

2003

Headquarters

Seestrasse 16,Küsnacht, Zurich 8700

Type of Company

Private

Industries

Investment Services & Portfolio Management

Company Description

Bellevue AM is an active, fundamental research-based manager which utilizes a bottom-up investment and anti-cyclical approach, aiming to generate above-average returns while keeping risk under control and well monitored. They screen and invest in promising family and owner-managed companies based in Switzerland or the broader European continent through our family of Entrepreneur funds. The firm has become very adept at identifying high growth potential in new and emerging markets, particularly on the African continent. In addition to global equity and fixed income funds, Bellevue AM successfully manage multi-asset funds. A diverse family of ETF strategies (asset allocation with ETFs) rounds out the holistic profile. The firm’s in-house capital market research specialists systematically identify the most attractive asset classes, markets and sectors, as viewed from a holistic perspective. Their flagship investment vehicle, BB Biotech AG invests in fast-growing biotechnology companies that are developing and marketing innovative drugs. BB Biotech’s investment portfolio usually consists of 20 up to a maximum of 35 biotechnology companies. There are established, large-cap companies as well as small- and mid-cap companies in the portfolio. The asset classes available to BB Biotech are direct investments in the shares of listed companies, equity interests in unlisted companies, corporate bonds, and options on a range of underlying assets. Bellevue AM invests almost exclusively in stocks for liquidity and risk/return reasons. At least 90% of its shareholdings must be in listed companies, while always holding more than 50% of its assets in equity investments. Corporate bonds are an alternative primarily when stock market trends are negative. Options on the stocks of portfolio companies will be bought and sold at opportune times and as a means of hedging currency exposure.

Contact Data
Trying to get in touch with decision makers at Bellevue Asset Management? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
In The News
AWP OTS (Original Text Service)
January 17, 2020
EQS-Adhoc: BB Biotech AG closes the 2019 fiscal year with a profit
AWP OTS (Original Text Service)
October 18, 2019
EQS-Adhoc: BB Biotech AG publishes its interim report
Executives & Employees

Group Chief Executive Officer

Chief Financial Officer, Chief Operating Officer & Chief Risk Officer

Lead Portfolio Manager

Head-BioTech & Portfolio Manager

Co-Head of Sales Associate

Head Healthcare Funds & Mandates, Member of the Executive Board

Head, Investments & Products

Managing Director, Asset Management Bab N.V., Curaçao

Managing Director, Asset Management Bab N.V., Curaçao

Senior Portfolio Manager

Board of Directors

Chairman & Chief Executive Officer at US Oil & Gas PLC

Paths to Bellevue Asset Management
Potential Connections via
Relationship Science
You
Bellevue Asset Management
Investments
Details Hidden

Vivoryon Therapeutics NV is a biopharmaceutical company, which engages in the research and development of therapeutic products for the treatment of Alzheimer's disease. Its product pipeline includes PQ912, PBD-C06, and PQ1565. The company was founded by Hans-Ulrich Demuth and Konrad Glund on July 25, 1997 and is headquartered in Halle, Germany.

Details Hidden

POZEN, Inc. manufactures and markets pharmaceutical products. Its Pipeline products are PA Product Portfolio, which is focused on integrated aspirin therapies that enable the full power of aspirin by reducing its potential gastrointestinal damage. The firm PA Product Portfolio consists of PA8140 and PA32540. The company was founded by John R. Plachetka in 1996 and is headquartered in Raleigh, NC.

Details Hidden

Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA.

Investors
Details Hidden

Life Peer at United Kingdom House of Lords

Details Hidden

Life Peer at United Kingdom House of Lords

Details Hidden

Life Peer at United Kingdom House of Lords

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Bellevue Asset Management. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Bellevue Asset Management's profile does not indicate a business or promotional relationship of any kind between RelSci and Bellevue Asset Management.